Folate receptor targeted nanoparticles containing niraparib and doxorubicin for treatment of high grade serous ovarian cancer

Lucy Lu Wang, James Evans, Lubabah Ahmed, Christine Allen

TL;DR

This paper presents a novel nanoparticle formulation designed to deliver a synergistic combination of niraparib (a PARP inhibitor) and doxorubicin for high-grade serous ovarian cancer (HGSOC). By encapsulating these drugs at a specific ratio within folate-targeted liposomes, the researchers aim to improve therapeutic efficacy and reduce systemic toxicity, addressing a critical need in ovarian cancer treatment.

What Problem Does This Paper Address?

Ovarian cancer (OC) remains a leading cause of cancer-related deaths, with limited improvements in survival rates. While combination chemotherapy is a known strategy to enhance therapeutic response and manage toxicities, achieving optimal synergistic drug ratios and ensuring their targeted delivery to cancer cells is challenging. Traditional chemotherapy often leads to dose-limiting toxicities, particularly hematological ones. The development of nanoparticle-based drug delivery systems, like Vyxeos®, has shown promise in improving survival and reducing toxicity by delivering synergistic drug combinations at specific ratios. This study addresses the need for a similarly effective approach for ovarian cancer, focusing on the combination of a PARP inhibitor (niraparib) and doxorubicin, which has shown synergistic potential but faces challenges in targeted delivery and toxicity management.

Methods

The researchers employed a multi-faceted approach:

  • In vitro Drug Combination Screening: They screened various molar ratios of niraparib (NIRB) and doxorubicin (DOX) in a panel of HGSOC cell lines to identify synergistic combinations. The combination index (CI) was calculated using CompuSyn software, with thresholds for synergy (CI ≤ 0.9), additivity (0.9 < CI < 1.1), and antagonism (CI ≥ 1.1).
  • Folate Receptor Alpha (FRα) Expression Analysis: Flow cytometry was used to assess FRα expression on different OC cell lines, as FRα is overexpressed in a significant portion of HGSOC tumors and serves as a target for active targeting.
  • Liposome Formulation and Characterization: They developed dual-loaded liposomes encapsulating NIRB and DOX. Active loading using a pH gradient and triethylammonium sucrose octasulfate (TEA&SOS) was employed. Folate targeting was achieved through post-insertion of folate-PEG5k-DSPE. Characterization included size determination (DLS), encapsulation efficiency (HPLC-UV), drug-to-lipid ratio, and drug release studies (in vitro release in BSA).
  • Cryogenic Transmission Electron Microscopy (Cryo-TEM): This technique was used to visualize the morphology of the liposomes and confirm the presence of drug deposits within the liposomal core, suggesting a solid core morphology that could contribute to sustained release.

Datasets

The study utilized a panel of four human ovarian cancer cell lines: OVCAR8, HEYA8, PEO1, and PEO4. These cell lines were chosen for their relevance to HGSOC and their varying characteristics, including platinum resistance and BRCA mutation status. The breast cancer cell line MCF7 was used as a negative control for FRα expression. No new benchmark datasets were introduced; rather, established cell lines were used for in vitro screening and characterization.

Key Insights and Ideas

  • Synergy is Ratio and Cell Line Dependent: The study highlights that the synergistic effect of NIRB and DOX is not universal but depends on the specific molar ratio and the genetic background of the cancer cell line. This underscores the importance of personalized approaches in combination therapy.
  • HR Proficiency Dictates Response: A crucial finding is that the combination of DOX and PARP inhibitors (like NIRB) can lead to antagonism in cell lines with proficient homologous recombination (HR) repair (e.g., intact BRCA2 function). This suggests that patients with HR-proficient tumors might not benefit from this combination and could even experience detrimental effects, emphasizing the need to stratify patients based on HR status.
  • Targeted Delivery Enhances Uptake: Folate targeting significantly increased the cellular uptake of liposomes in FRα-overexpressing OVCAR8 cells compared to unconjugated liposomes, demonstrating the efficacy of the active targeting strategy. This was not observed in FRα-low expressing HEYA8 cells, reinforcing the specificity of the targeting.
  • Solid Core for Sustained Release: The formation of an electron-dense drug core within the liposomes, confirmed by cryo-TEM, is hypothesized to contribute to the sustained release of NIRB and DOX, minimizing premature drug release in systemic circulation.

Key Results

  • Optimal Synergistic Ratio: The 10:1 molar ratio of NIRB:DOX demonstrated the most consistent synergistic or additive effects across most tested cell lines, particularly in HR-deficient settings.
  • Antagonism in HR-Proficient Cells: The PEO4 cell line, which exhibits BRCA2 mutation reversion (HR proficiency), showed antagonistic effects for the NIRB:DOX combination across all tested molar ratios.
  • Successful Dual Loading and Targeting: The researchers successfully formulated a nanoparticle that reproducibly encapsulated NIRB and DOX at a 9.4±0.6:1 molar ratio, closely approximating the target synergistic ratio. The folate-targeted liposomes showed significantly increased uptake in FRα-overexpressing cells.
  • Sustained Drug Release: In vitro release studies demonstrated minimal drug release from the NIRB-DOX-FA liposomes over a 5-day period, maintaining the encapsulated drug ratio and suggesting good payload stability.

Limitations and Future Work

The authors acknowledge several limitations and suggest future directions:

  • Limited Cell Line Panel: The study used a small panel of OC cell lines. Future work should involve screening a larger panel, including more platinum-resistant lines, to better model disease heterogeneity and identify potential responders.
  • HR Proficiency as a Biomarker: The findings suggest that HR proficiency might be an exclusion criterion for this treatment strategy. Further investigation is needed to confirm this and to identify biomarkers that can predict good versus bad responders.
  • Mechanistic Studies: While a potential synergistic mechanism involving dsDNA breaks is hypothesized, comparative mechanistic studies for NIRB and DOX are needed.
  • In Vivo Validation: The current study is primarily in vitro. Future work should focus on in vivo studies to evaluate the therapeutic efficacy, pharmacokinetics, biodistribution, and toxicity of the NIRB-DOX-FA liposomes in relevant animal models.
  • Objective Confirmation of Drug State: Techniques like X-ray diffraction could be used to objectively confirm the solid core morphology and the state of the intraliposomal drug molecules.

Summary updated

Abstract

Abstract Combination chemotherapy is an established approach used to manage toxicities while eliciting an enhanced therapeutic response. Delivery of combinations of drugs in specific molar ratios has been considered a means to achieve synergistic effects resulting in improvements in efficacy while minimizing dose related adverse drug reactions. The benefits of this approach have been realized with the FDA approval of Vyxeos ® , the first liposome formulation to deliver a synergistic drug combination leading to improved overall survival against standard of care. In the current study, we demonstrate the synergistic potential of the PARP inhibitor niraparib and doxorubicin for the treatment of ovarian cancer. Through in vitro screening in a panel of ovarian cancer cell lines, we find that niraparib and doxorubicin demonstrate consistent synergy/additivity at the majority of evaluated molar ratio combinations. Further to these findings, we report formulation of a nanoparticle encapsulating our identified synergistic combination. We describe a rational design process to achieve highly stable liposomes that are targeted with folate to folate-receptor-alpha, which is known to be overexpressed on the surface of ovarian cancer cells. With this approach, we aim to achieve targeted delivery of niraparib and doxorubicin at a pre-determined synergistic molar ratio via increased receptor-mediated endocytosis. Graphical Abstract
BibTeX
@inproceedings{wang2023folate,
  author = {Lucy Lu Wang and James Evans and Lubabah Ahmed and Christine Allen},
  title = {{Folate receptor targeted nanoparticles containing niraparib and doxorubicin for treatment of high grade serous ovarian cancer}},
  booktitle = {Scientific},
  year = {2023},
  doi = {10.1038/s41598-023-28424-3},
}
Figure